TGTX’s $750M Credit Facility and Tripled Buyback Signal Deep Institutional Conviction, Resetting the Bull Case

The setup for TGTX's explosive run was a classic expectation gap. In February, the company delivered a severe earnings miss that the market initially punished. The stock dropped 5.19% in pre-market trading following the report, a clear "sell the news" reaction to the bottom line shortfall.

The core of that miss was stark. TG Therapeutics posted earnings of $0.14 per share, which fell far short of the forecast of $0.37. That's a surprise of -62.16%, a massive gap that overshadowed nearly everything else. Yet, the revenue story was a different narrative. The company posted revenues of $192.57 million, which exceeded forecasts by 2.03% against an estimate of $188.73 million. This beat was driven by strong sales of its lead product, BRIUMVI.

So, the initial market reaction was straightforward: the severe EPS miss was priced in, and the stock sold off. The beat on revenue was not enough to offset the disappointment on profitability. This February print established the starting point for a subsequent narrative reset. The stock's subsequent 72% run since then was not a simple "beat and raise" on that single quarter, but a recalibration of expectations that eventually overshadowed that initial miss.

The Catalyst Reset: Credit Facility and the $8 Million Bet

The market's initial reaction to the Q4 miss was a classic "sell the news" event. But the subsequent run has been driven by a series of catalysts that reset the narrative from financial vulnerability to strategic strength. The cornerstone of this shift is a major capital allocation move.

In March, TG Therapeutics announced a new five-year, $750 million senior secured credit facility. Crucially, the company will use $250 million of this new debt to repay its existing facility, netting a clean $500 million in non-dilutive capital. This isn't just about raising cash; it's about improving the balance sheet's quality. The new terms offer greater scale and flexibility, providing a substantial financial cushion to fund operations and growth without issuing new shares.

The narrative was further reinforced by a new institutional bet. In late February, ACT Capital Management disclosed a new position in TG Therapeutics worth $8.02 million, making it their fifth-largest holding. For a fund, this is a meaningful allocation, representing 6.5% of its reportable U.S. equity assets. This isn't a small, speculative bet; it's a concentrated conviction play on a single biotech stock. The timing is telling-this position was established just weeks after the severe earnings miss, suggesting the fund saw value where the broader market saw disappointment.

Together, these moves created a powerful expectation reset. The $750 million facility and the tripled buyback authorization shifted the focus from the Q4 EPS shortfall to a story of enhanced financial flexibility and management confidence. The ACT Capital stake added external validation, showing that sophisticated investors were willing to commit capital to the new setup. The market's subsequent rally indicates it priced in this new reality: a company with a stronger balance sheet, a clear path to return capital, and a new institutional believer.

The Bull Case: Why the Fund Remains Bullish Despite the Miss

The bull case for TGTX is a straightforward bet on the future, built on a clean break from the past. The severe EPS miss in February is now firmly in the rearview. The market's focus has shifted decisively to the high-growth trajectory laid out in the company's 2026 guidance. This creates a clear expectation gap: the stock trades at a multiple that seems to price in only the recent disappointment, while the forward view points to explosive expansion.

The core of the bull thesis is the revenue target. Management has guided for approximately $875-900 million in total global revenue for 2026. That represents a staggering 40%+ year-over-year increase from the $616.3 million generated in 2025. This isn't a modest step-up; it's a doubling down on the momentum of BRIUMVI, which already delivered 92% annual growth last year. The guidance implies the commercial ramp is just beginning, with global availability expanding and adoption accelerating. For investors, this is the primary driver of value. The market is now pricing in the future, not the past.

Valuation provides the final piece of the puzzle. With a trailing P/E of 10.86, the stock trades at a discount to many peers in the biotech sector. This low multiple suggests the market is still discounting the company's growth story, perhaps due to lingering concerns from the Q4 report. Yet, the consensus price target tells a different story. Analysts see significant upside, with an average target of $50.75 and a consensus price target of $44.43. That implies a potential move of over 40% from recent levels. The bull case is that the stock's valuation will eventually catch up to its guidance.

The next major test of this thesis arrives in about two months. The market will get its first look at whether the company is on track to hit its ambitious targets when it reports Q1 2026 earnings around May 4, 2026. The guidance reset and the new capital structure have created a favorable setup. The bull case is that the severe miss is priced in, and the stock is now positioned to reward investors who bought the rumor of high-growth execution. The catalyst is clear: meet or beat the 2026 revenue target, and the expectation gap will close.